Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is a global manufacturing company, primarily focused on producing scientific instruments and consumables for the life sciences and diagnostic industries. With a culture of continuous improvement and a solid track record of organic growth and strategic acquisitions, Danaher has consistently expanded its market share and revenue. Despite some short-term headwinds, such as a seasonal decline in respiratory testing, Danaher's diversified portfolio and strong leadership position in key markets make it a solid investment opportunity for long-term growth.

Bears say

Danaher is facing declining sales in its Life Sciences division and specifically in instrument demand, showing a trend likely to continue due to market uncertainty and biotech funding recovery lag. While the company prioritizes sustainability and has a diverse leadership team, its global manufacturing footprint and potential for high growth end-markets not recovering pose risks. The recent 2Q26 guidance expects core revenue growth in low single digits due to various factors such as geopolitical and macro headwinds, with risks including geopolitical disruptions and changes to forecasted end-market growth rates.

Danaher (DHR) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 16 analysts, Danaher (DHR) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $239.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $239.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.